CoChat
Sign Up
Cited by 103

Snus: a compelling harm reduction alternative to cigarettes

Clarke, Elizabeth, Thompson, Keith, Weaver, Sarah, Thompson, Joseph, O’Connell, Grant·2019·Harm Reduction Journal
DOI 10.1186/s12954-019-0335-1PMC PMC6882181
Open this paper in CoChat — free account

Abstract

Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily “oral tobacco” use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12954-019-0335-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 93

  1. [4]International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 89. 2007. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono89.pdf. Accessed 07 Feb 2019. PMC4781254 18335640
  2. [5]Rutqvist LE Curvall M Hassler T Ringberger T Wahlberg I Swedish snus and the GothiaTek® standard Harm Reduct J. 2011 8 11 10.1186/1477-7517-8-11 21575206 PMC3119032 · DOI
  3. [7]Rodu B Jansson JH Eliasson M The low prevalence of smoking in the Northern Sweden MONICA study, 2009 Scand J Public Health. 2013 41 808 811 10.1177/1403494813504836 24052339 · DOI
  4. [14]Peto R Darby S Deo H Silcocks P Whitely E Doll R Smoking, smoking cessation and lung cancer in the UK since 1950: combination of national statistics with two case-control studies BMJ. 2000 321 323 329 10.1136/bmj.321.7257.323 10926586 PMC27446 · DOI
  5. [15]The United States Surgeon General. 2010 Surgeon General’s report - how tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. 2010. https://www.cdc.gov/tobacco/data_statistics/sgr/2010/index.htm. Accessed 04 Feb 2019. 21452462
  6. [16]International Agency for Research on Cancer. Personal habits and indoor combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 100E. 2012. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100E.pdf. Accessed 07 Feb 2019. PMC4781577 23193840
  7. [19]Ferlay J Steliarova-Foucher E Lortet-Tieulent J Rosso S Coebergh JW Comber H Forman D Bray F Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer. 2013 49 1374 1403 10.1016/j.ejca.2012.12.027 23485231 · DOI
  8. [22]Nutt DJ Philips LD Balfour D Curran HV Dockrell M Foulds J Fagerstöm K Letlape K Milton A Polosa R Ramsey J Sweanor D Estimating the harms of nicotine-containing products using the MDCA approach Eur Addict Res. 2014 20 218 225 10.1159/000360220 24714502 · DOI
  9. [24]Lee PN Epidemiological evidence relating snus to health - an updated review based on recent publications Harm Reduct J. 2013 10 36 10.1186/1477-7517-10-36 24314326 PMC4029226 · DOI
  10. [26]Levy DT Mumford EA Cummins KM Gilpin EA Giovino EA Hyland A Sweanor D Warner KE The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts Cancer Epidemiol Biomarkers Prev. 2004 13 2035 2042 15598758
  11. [27]Gartner CE Hall WD Vos T Bertram MY Wallace AL Lim SS Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study Lancet 2007 369 2010 2014 10.1016/S0140-6736(07)60677-1 17498798 · DOI
  12. [28]Ramström L Borland R Wikmans T Patterns of smoking and snus use in sweden: implications for public health Int J Environ Res Public Health. 2016 13 E1110 10.3390/ijerph13111110 27834883 PMC5129320 · DOI
  13. [29]Asplund K Nasic S Janlert U Stegmayr B Smokeless tobacco as a possible risk factor for stroke in men – a nested case-control study Stroke. 2003 34 1754 1759 10.1161/01.STR.0000076011.02935.A1 12775887 · DOI
  14. [30]Rodu B Cole P Lung cancer mortality: comparing Sweden with other countries in the European Union Scand J Public Health. 2009 37 481 486 10.1177/1403494809105797 19535408 · DOI
  15. [31]Luo J Ye W Zendehdel K Adam J Adami HO Boffetta P Nyrén O Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study Lancet. 2007 369 2015 2020 10.1016/S0140-6736(07)60678-3 17498797 · DOI · Paper page
  16. [32]Boffetta P Aagnes B Weiderpass E Andersen A Smokeless tobacco use and risk of cancer of the pancreas and other organs Int J Cancer. 2005 114 992 995 10.1002/ijc.20811 15645430 · DOI
  17. [34]Bolinder G Alfredsson L Englund A de Faire U Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers Am J Public Health. 1994 84 399 404 10.2105/AJPH.84.3.399 8129055 PMC1614817 · DOI
  18. [35]Hergens MP Alfredsson L Bolinder G Lambe M Pershagen G Ye W Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men J Intern Med. 2007 262 351 359 10.1111/j.1365-2796.2007.01816.x 17697156 · DOI · Paper page
  19. [36]Arefalk G Hergens MP Ingelsson E Arnlöv J Michaëlsson K Lind L Ye W Nyrén O Lambe M Sundström J Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts Eur J Prev Cardiol. 2012 19 1120 1127 10.1177/1741826711420003 21828223 · DOI · Paper page
  20. [37]Huhtasaari F Asplund K Lundberg V Stegmayr B Wester PO Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ. 1992 305 1252 1256 10.1136/bmj.305.6864.1252 1477567 PMC1883750 · DOI
  21. [38]Huhtasaari F Lundberg V Eliasson M Janlert U Asplund K Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men J Am Coll Cardiol. 1999 34 1784 1790 10.1016/S0735-1097(99)00409-X 10577570 · DOI
  22. [39]Hergens MP Ahlbom A Andersson T Pershagen G Swedish moist snuff and myocardial infarction among men Epidemiology. 2005 16 12 16 10.1097/01.ede.0000147108.92895.ba 15613940 · DOI
  23. [40]Haglund B Eliasson M Stenbeck M Rosén M Is moist snuff use associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden Scand J Public Health. 2007 35 618 622 10.1080/14034940701436949 17852996 · DOI · Paper page
  24. [41]Wennberg P Eliasson M Hallmans G Johansson L Boman K Jansson JH The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking J Intern Med. 2007 262 360 367 10.1111/j.1365-2796.2007.01813.x 17697157 · DOI
  25. [42]Janzon E Hedblad B Swedish snuff and incidence of cardiovascular disease A population-based cohort study. BMC Cardiovasc Disord. 2009 9 21 10.1186/1471-2261-9-21 19473535 PMC2695419 · DOI
  26. [43]Hansson J Pedersen NL Galanti MR Andersson T Ahlbom A Hallqvist J Magnusson C Use of snus and risk for cardiovascular disease: results from the Swedish twin registry J Intern Med. 2009 265 717 724 10.1111/j.1365-2796.2009.02081.x 19504754 · DOI · Paper page
  27. [44]Hansson J Galanti MR Hergens MP Fredlund P Ahlbom A Alfredsson L Bellocco R Eriksson M Hallqvist J Hedblad J Jansson JH Nilsson P Pedersen N Trolle Lagerros Y Ostergren PO Magnusson C Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies Eur J Epidemiol. 2012 27 771 779 10.1007/s10654-012-9704-8 22722951 · DOI · Paper page
  28. [45]Hergens MP Galanti R Hansson J Fredlund P Ahlbom A Alfredsson L Bellocco R Erikssen M Fransson EI Hallqvist J Jansson JH Knutsson A Pedersen N Lagerros YT Ostergren PO Magnusson C Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation Epidemiology. 2014 25 872 876 10.1097/EDE.0000000000000169 25166877 · DOI · Paper page
  29. [46]Hergens MP Lambe M Pershagen G Terent A Ye W Smokeless tobacco and the risk of stroke Epidemiology. 2008 19 794 799 10.1097/EDE.0b013e3181878b33 18854704 · DOI
  30. [47]Hansson J Galanti MR Hergens MP Fredlund P Ahlbom A Alfredsson L Bellocco R Engström G Eriksson M Hallqvist J Hedblad B Jansson JH Pedersen NL Trolle Lagerros Y Ostergren PO Magnusson C Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival J Intern Med. 2014 276 87 95 10.1111/joim.12219 24548296 · DOI · Paper page
  31. [48]Lee PN Summary of the epidemiological evidence relating snus to health Regul Toxicol Pharmacol. 2011 59 197 214 10.1016/j.yrtph.2010.12.002 21163315 · DOI
  32. [49]Hirsch JM Hedner J Wernstedt L Lundberg J Hedner T Hemodynamic effects of the use of snuff Clin Pharmacol Ther. 1992 52 394 401 10.1038/clpt.1992.161 1424411 · DOI
  33. [50]Bolinder G de Faire U Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users Am J Hypertens. 1998 11 1153 1163 10.1016/S0895-7061(98)00137-X 9799031 · DOI
  34. [51]Rohani M Agewall S Oral snuff impairs endothelial function in healthy snuff users J Intern Med. 2004 255 379 383 10.1046/j.1365-2796.2003.01279.x 14871462 · DOI
  35. [52]Bolinder GM Ahlborg BO Lindell JH Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey J Intern Med. 1992 232 327 334 10.1111/j.1365-2796.1992.tb00593.x 1402636 · DOI
  36. [53]Hergens MP Lambe M Pershagen G Ye W Risk of hypertension amongst Swedish male snuff users: a prospective study J Intern Med. 2008 264 187 194 10.1111/j.1365-2796.2008.01939.x 18393959 · DOI · Paper page
  37. [54]Sundström D Waldenborg M Emilsson K Acute effects on the ventricular function in Swedish snuffers: an echocardiographic study Clin Physiol Funct Imaging. 2012 32 106 113 10.1111/j.1475-097X.2011.01062.x 22296630 · DOI
  38. [55]Björkman F Edin F Mattsson CM Larsen F Ekblom B Regular moist snuff dipping does not affect endurance exercise performance PLoS One. 2017 12 e0181228 10.1371/journal.pone.0181228 28704507 PMC5509427 · DOI
  39. [56]Eliasson M Lundblad D Hägg E Cardiovascular risk factors in young snuff users and cigarette smokers J Intern Med. 1991 230 17 22 10.1111/j.1365-2796.1991.tb00401.x 2066707 · DOI
  40. [57]Wennmalm A Benthin G Granström EF Persson L Petersson AS Winell S Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men Circulation. 1991 83 1698 1704 10.1161/01.CIR.83.5.1698 2022025 · DOI
  41. [58]Eliasson M Asplund K Evrin PE Lundblad D Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin The Northern Sweden MONICA study. Atherosclerosis. 1995 113 41 53 7755654
  42. [59]Wallenfeldt K Hulthe J Bokemark L Wikstrand J Fagerberg B Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men J Intern Med. 2001 250 492 501 10.1046/j.1365-2796.2001.00917.x 11902817 · DOI
  43. [60]Johansson SE Sundquist K Qvist J Sundquist J Smokeless tobacco and coronary heart disease a 12-year follow-up study Eur J Cardiovasc Prev Rehabil. 2005 12 387 392 10.1097/01.hjr.0000169189.22302.99 16079648 · DOI
  44. [61]Norberg M Stenlund H Lindahl B Boman K Weinehall L Contribution of Swedish moist snuff to the metabolic syndrome: a wolf in sheep's clothing? Scand J Public Health. 2006 34 576 583 10.1080/14034940600665143 17132590 · DOI · Paper page
  45. [62]Byhamre ML Gustafsson PE Jansson JH Wennberg M Hammarström A Wennberg P Snus use during the life-course and risk of the metabolic syndrome and its components Scand J Public Health. 2017 45 733 740 10.1177/1403494817706631 28673132 · DOI · Paper page
  46. [64]Araghi M Rosaria Galanti M Lundberg M Lager A Engström G Alfredsson L Knutsson A Norberg M Sund M Wennberg P Trolle Lagerros Y Bellocco R Pedersen NL Östergren PO Magnusson C Use of moist oral snuff (snus) and pancreatic cancer: Pooled analysis of nine prospective observational studies Int J Cancer. 2017 141 687 693 10.1002/ijc.30773 28486772 · DOI · Paper page
  47. [65]Sponsiello-Wang Z Weitkunat R Lee PN Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America BMC Cancer. 2008 8 356 10.1186/1471-2407-8-356 19046421 PMC2612688 · DOI
  48. [66]Lee PN Hamling J The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews BMC Cancer 2009 9 256 10.1186/1471-2407-9-256 19638246 PMC3087330 · DOI
  49. [67]Persson PG Carlsson S Svanström L Ostenson CG Efendic S Grill V Cigarette smoking, oral moist snuff use and glucose intolerance J Intern Med. 2000 248 103 110 10.1046/j.1365-2796.2000.00708.x 10947888 · DOI
  50. [68]Eliasson M Asplund K Nasic S Rodu B Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study J Intern Med. 2004 256 101 110 10.1111/j.1365-2796.2004.01344.x 15257722 · DOI · Paper page
  51. [69]Wändell PE Bolinder G de Faire U Hellénius ML Association between metabolic effects and tobacco use in 60-year-old Swedish men Eur J Epidemiol. 2008 23 431 434 10.1007/s10654-008-9260-4 18470624 · DOI
  52. [70]Neumann A Norberg M Schoffer O Norström F Johansson I Klug SJ Lindholm L Risk equations for the development of worsened glucose status and type 2 diabetes mellitus in a Swedish intervention program BMC Public Health. 2013 13 1014 10.1186/1471-2458-13-1014 24502249 PMC3871001 · DOI
  53. [71]Rasouli B Andersson T Carlsson PO Grill V Groop L Martinell M Midthjell K Storm P Tuomi T Carlsson S Use of Swedish smokeless tobacco (snus) and the risk of Type 2 diabetes and latent autoimmune diabetes of adulthood (LADA) Diabet Med. 2017 34 514 521 10.1111/dme.13179 27353226 · DOI · Paper page
  54. [72]Östenson CG Hilding A Grill V Efendic S High consumption of smokeless tobacco ("snus") predicts increased risk of type 2 diabetes in a 10-year prospective study of middle-aged Swedish men Scand J Public Health. 2012 40 730 737 10.1177/1403494812459814 23117209 · DOI · Paper page
  55. [73]Carlsson S Andersson T Araghi M Galanti R Lager A Lundberg M Nilsson P Norberg M Pedersen NL Trolle-Lagerros Y Magnusson C Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results from five pooled cohorts J Intern Med. 2017 281 398 406 10.1111/joim.12592 28164394 · DOI · Paper page
  56. [74]Lee PN Thornton AJ The relationship of snus use to diabetes and allied conditions Regul Toxicol Pharmacol. 2017 91 86 92 10.1016/j.yrtph.2017.10.017 29061372 · DOI
  57. [75]Axell T A prevalence study of oral mucosal lesions in an adult Swedish population Odontol Revy Suppl. 1976 36 1 103 186740
  58. [76]Lewin F Norell SE Johansson H Gustavsson P Wennerberg J Biörklund A Rutqvist LE Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. A population-based case referent study in Sweden Cancer. 1998 82 1367 1375 10.1002/(SICI)1097-0142(19980401)82:7<1367::AID-CNCR21>3.0.CO;2-3 9529030 · DOI
  59. [77]Schildt EB Eriksson M Hardell L Magnuson A Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study Int J Cancer. 1998 77 341 346 10.1002/(SICI)1097-0215(19980729)77:3<341::AID-IJC6>3.0.CO;2-O 9663593 · DOI
  60. [78]Rosenquist K Wennerberg J Schildt EB Bladström A Hansson BG Andersson G Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden Acta Otolaryngol. 2005 125 991 998 10.1080/00016480510043440 16193590 · DOI
  61. [79]Bundgaard T Wildt J Frydenberg M Elbrønd O Nielsen JE Case-control study of squamous cell cancer of the oral cavity in Denmark Cancer Causes Control. 1995 6 57 67 10.1007/BF00051681 7718736 · DOI
  62. [80]Roosaar A Johansson AL Sandborgh-Englund G Axéll T Nyrén O Cancer and mortality among users and nonusers of snus Int J Cancer. 2008 123 168 173 10.1002/ijc.23469 18412245 · DOI
  63. [81]Hirsch JM Wallström M Carlsson AP Sand L Oral cancer in Swedish snuff dippers Anticancer Res. 2012 10 3327 3330 22843910
  64. [85]Kallischnigg G Weitkunat R Lee PN Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United States BMC Oral Health. 2008 8 13 10.1186/1472-6831-8-13 18452601 PMC2390522 · DOI
  65. [86]Neville BW Day TA Oral cancer and precancerous lesions CA Cancer J Clin. 2002 52 4 195 215 10.3322/canjclin.52.4.195 12139232 · DOI
  66. [88]Modéer T Lavstedt S Xhlund C Relation between tobacco consumption and oral health in Swedish schoolchildren Acta Odontol Scand. 1980 38 233 237 6937088
  67. [89]Wickholm S Söder PO Galanti MR Söder B Klinge B Periodontal disease in a group of Swedish adult snuff and cigarette users Acta Odontol Scand. 2004 62 333 338 10.1080/00016350410001801 15848977 · DOI
  68. [90]Rolandsson M Hellqvist L Lindqvist L Hugoson A Effects of snuff on the oral health status of adolescent males: a comparative study Oral Health Prev Dent. 2005 3 77 85 16173384
  69. [91]Bergström J Keilani H Lundholm C Rådestad U Smokeless tobacco (snuff) use and periodontal bone loss J Clin Periodontol. 2006 33 549 554 10.1111/j.1600-051X.2006.00945.x 16899097 · DOI
  70. [92]Montén U Wennström JL Ramberg P Periodontal conditions in male adolescents using smokeless tobacco (moist snuff) J Clin Periodontol. 2006 33 863 868 10.1111/j.1600-051X.2006.01005.x 17092238 · DOI
  71. [93]Andersson G Axéll T Clinical appearance of lesions associated with the use of loose and portion-bag packed Swedish moist snuff: a comparative study J Oral Pathol Med. 1989 18 2 7 10.1111/j.1600-0714.1989.tb00722.x 2746515 · DOI
  72. [94]Frithiof L Anneroth G Lasson U Sederholm C The snuff-induced lesion. A clinical and morphological study of a Swedish material Acta Odontol Scand. 1983 41 53 64 10.3109/00016358309162303 6575574 · DOI
  73. [95]Hugoson A Rolandsson M Periodontal disease in relation to smoking and the use of Swedish snus: epidemiological studies covering 20 years (1983-2003) J Clin Periodontol. 2011 38 809 816 10.1111/j.1600-051X.2011.01749.x 21762421 · DOI · Paper page
  74. [96]Hirsch JM Livian G Edward S Noren JG Tobacco habits among teenagers in the city of Göteborg, Sweden, and possible association with dental caries Swed Dent J. 1991 15 117 123 1876978
  75. [97]Hugoson A Hellqvist L Rolandsson M Birkhed D Dental caries in relation to smoking and the use of Swedish snus: epidemiological studies covering 20 years (1983-2003) Acta Odontol Scand. 2012 70 289 296 10.3109/00016357.2011.654247 22339319 · DOI
  76. [98]Hellqvist L Rolandsson M Hugoson A Lindström P Birkhed D Dental caries and associated factors in a group of Swedish snus users Swed Dent J. 2015 39 47 54 26529841
  77. [99]Wetter DW McClure JB de Moor C Cofta-Gunn L Cummings S Cinciripini PM Gritz ER Concommitant use of cigarettes and smokeless tobacco: prevalence, correlates, and predictors of tobacco cessation Prev Med. 2002 34 638 648 10.1006/pmed.2002.1032 12052025 · DOI
  78. [102]Rodu B Nasic S Cole P Tobacco use among Swedish schoolchildren Tob Control. 2005 14 6 405 408 10.1136/tc.2005.011429 16319364 PMC1748133 · DOI
  79. [103]Norberg M, Lundqvist G, Nilsson M, Gilljam H, Weinehall L. Changing patterns of tobacco use in a middle-aged population – the role of snus, gender, age, and education. Glob Health Action. 2011;4. PMC3118776 21695071
  80. [104]Lee PN Health risks related to dual use of cigarettes and snus - a systematic review Regul Toxicol Pharmacol. 2014 69 125 134 10.1016/j.yrtph.2013.10.007 24184647 · DOI
  81. [105]Wikström AK Stephansson O Cnattingius S Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff Hypertension. 2010 55 1254 1259 10.1161/HYPERTENSIONAHA.109.147082 20231527 · DOI
  82. [106]Bates C Fagerström K Jarvis MJ Kunze M McNeill A Ramström L European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health Tob Control. 2003 12 360 367 10.1136/tc.12.4.360 14660767 PMC1747769 · DOI
  83. [108]Joffer J Burell G Bergström E Stenlund H Sjörs L Jerdén L Predictors of smoking among Swedish adolescents BMC Public Health. 2014 14 1296 10.1186/1471-2458-14-1296 25518992 PMC4300986 · DOI
  84. [109]Gmel G Clair C Rougemont-Bücking A Grazioli VS Daeppen JB Mohler-Kuo M Studer J Snus and snuff use in Switzerland among young men: are there beneficial effects on smoking? Nicotine Tob Res. 2018 20 1301 1309 10.1093/ntr/ntx224 29059425 · DOI
  85. [110]Furberg H Lichtenstein P Pedersen NL Bulik CM Lerman C Sullivan PF Snus use and other correlates of smoking cessation in the Swedish Twin Registry Psychol Med. 2008 38 1299 1308 10.1017/S0033291707002346 18680625 PMC2914546 · DOI
  86. [111]Stenbeck M Hagquist C Rosén M The association of snus and smoking behaviour: a cohort analysis of Swedish males in the 1990s Addiction. 2009 104 1579 1585 10.1111/j.1360-0443.2009.02661.x 19686528 · DOI
  87. [112]Lund KE Scheffels J McNeill A The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies Addiction. 2011 106 162 167 10.1111/j.1360-0443.2010.03122.x 20883459 PMC3021722 · DOI · Paper page
  88. [113]Rutgvist LE Population-based survey of cessation aids used by Swedish smokers Harm Reduct J. 2012 9 38 10.1186/1477-7517-9-38 23206988 PMC3539856 · DOI
  89. [114]Rodu B Phillips CV Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey Harm Reduct J. 2008 5 18 10.1186/1477-7517-5-18 18500993 PMC2427022 · DOI
  90. [115]Caldwell B Burgess C Crane J Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers Nicotine Tob Res. 2010 12 179 183 10.1093/ntr/ntp189 20064899 · DOI
  91. [116]Joksić G Spasojević-Tišma V Antić R Nilsson R Rutqvist LE Randomised, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation Harm Reduct J. 2011 8 25 10.1186/1477-7517-8-25 21914165 PMC3186733 · DOI · Paper page
  92. [117]Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, Begh R, Farley A, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database of Systematic Reviews 2016, Issue 10. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005231.pub3/pdf/CDSR/CD005231/CD005231.pdf. Accessed 16th July 2019. PMC6463938 27734465 · DOI
  93. [118]Klimisch HJ Andreae M Tillmann U A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data Regul Toxicol Pharmacol. 1997 25 1 1 5 10.1006/rtph.1996.1076 9056496 · DOI

Cited by

Sorted by citations

Authors
Clarke, E., Thompson, K., Weaver, S., Thompson, J., & O’Connell, G.
ORCID
Clarke, Elizabeth
Venue
Harm Reduction Journal
Publisher
Springer Science and Business Media LLC
Published
2019-11-27
Volume
16
Issue
1
ISSN
1477-7517
DOI
10.1186/s12954-019-0335-1
PMC
PMC6882181
Cited by
103
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review